person · Reporting owner
Troutman William Wilson
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | CFO and Secretary | February 07, 2022 | February 28, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eton Pharmaceuticals, Inc.
Report date February 07, 2022 · Filed February 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.78 · Expires 2032-02-07 | Direct | 671,200 |
Reported balance
After 2022-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-07 · Grant · Acquired 15,000 · Balance 671,200 F1: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2022 Filed Feb 28, 2022 16:32 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 15,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001493152-22-005615 · ownership.xml · derivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,200 Underlying: Common Stock · 15,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 7, 2026. Read SEC document |
| August 20, 2021 Filed Aug 20, 2021 16:08 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 5,000 | $4.43 | $22,150.00 |
DisclosureSEC source: 0001493152-21-020809 · form4.xml · nonDerivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,027 Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 125,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001493152-21-010522 · ownership.xml · derivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,200 Underlying: Common Stock · 125,000 shares Expires 2031-05-03 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on May 3, 2025. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 16:56 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 186,200 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001493152-20-004059 · ownership.xml · derivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,200 Underlying: Common Stock · 186,200 shares Expires 2030-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments form the date of grant until fully vested and exercisable on March 12, 2024. Read SEC document |
| February 20, 2019 Filed Mar 8, 2019 16:31 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001209191-19-018106 · doc4.xml · derivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on February 20, 2023. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 19:07 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | PurchaseCommon Stock | 5,000 | $6.00 | $30,000.00 |
DisclosureSEC source: 0001209191-18-058822 · doc4.xml · nonDerivative · entry 1 Troutman William Wilson · CIK 0001756102 · CFO, Treasurer & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.